Using Technology to Better Understand What Goes Wrong in Cancer

Using Technology to Better Understand What Goes Wrong in Cancer

Cancer-News

3 months
30 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Zhibo Ma, PhD of @salkinstitute explains mapping normal breast development to try and better understand cancer.

__________

Breast cancer is one of the most common cancers, and some types are among the hardest to treat. The different types and presence of many different cells makes it difficult to target these tumors. Scientists at the Salk Institute have now used state-of - the-art technology to test each cell during normal breast development to understand what happens wrongly in cancer.

The results of the group, published in the Cell Reports on 8 October 2019 and distributed in a free online resource, lay the foundations for understanding normal breast growth and can lead to new strategies for tumor control.

"In order to understand what goes wrong in breast cancer, we need to first understand how normal development works," says Geoffrey Wahl, a professor in the Gene Expression Laboratory and senior author of the paper. "This study represents a major step in that direction, as we were able to profile each cell during breast development. We expect this information to be a valuable hypothesis-generating resource for the mammary gland community."

Two major cell types that are often implicated in breast cancer are found in mature breast tissue, luminary cells and basal cells. Luminal cells line the ducts and make milk while basal cells around the ducts contract to extract milk. The scientists were interested in what drives the molecular changes that control how stem cells become specialized in these cell types during growth. In particular, they explored how DNA packaging inside the cell, known as chromatin, could make certain genes accessible or unavailable to influence gene expression and growth.

Read here: https://www.oncologytube.com/video/mapping-the-usual-breast-development-to-recognize-cancer-better

Up Next Autoplay
EZH2 in Triple Negative Breast Cancer: What's Next in Research? @Ramon_Parsons @IcahnMountSinai
EZH2 in Triple Negative Breast Cancer: What's Next in Research? @Ramon_Parsons @IcahnMountSinai
Category: Breast Cancer
2 Views
Mount Sinai Health System 2 weeks
EZH2 in Triple Negative Breast Cancer @Ramon_Parsons @IcahnMountSinai
EZH2 in Triple Negative Breast Cancer @Ramon_Parsons @IcahnMountSinai
Category: Breast Cancer
33 Views
Mount Sinai Health System 2 weeks
SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine
SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine
Category: Breast Cancer
31 Views
ash 4 weeks
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
MacroGenics Presents Results from the SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
Category: Breast Cancer
17 Views
Cancer-News 4 weeks
Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19
Prognostic Marker in Operable Breast Cancer: How This Affects Clinicians? #SABCS19
Category: Breast Cancer
6 Views
ash 4 weeks
Prognostic Marker in Operable Breast Cancer #SABCS19
Prognostic Marker in Operable Breast Cancer #SABCS19
Category: Breast Cancer
22 Views
admin 4 weeks
The FLEX Real World Data #SABCS19 @BaptistHealthSA
The FLEX Real World Data #SABCS19 @BaptistHealthSA
Category: Breast Cancer
26 Views
admin 4 weeks
Agendia Presents New Data at #SABCS19 in Breast Cancer
Agendia Presents New Data at #SABCS19 in Breast Cancer
Category: Breast Cancer
9 Views
admin 4 weeks
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage...
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score® to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage...
Category: Breast Cancer
13 Views
Cancer-News 1 month
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
19 Views
cancernewsupdate 1 month